Phathom CEO Sees 'Inertia,' Not Resistance, As It Offers $0 Copays On Voquezna
Phathom's CEO says doctors are stuck in habit, so a $0 copay is offered only through BlinkRx, with benefits building over several quarters.
Doctors are not pushing back on Voquezna, they are simply stuck in habit, Phathom Pharmaceuticals CEO Steve Basta said on the company's third-quarter earnings call Thursday, so the company now offers a $0 copay only through its BlinkRx mail-order pharmacy partner. Phathom, a commercial-stage maker of gastrointestinal drugs, reported $84.7 million in third-quarter net revenue.
Inertia, not resistance
Asked where doctors resist BlinkRx, Basta said Phathom is "not actually seeing anything we would describe as resistance but rather just inertia." Patients are comfortable at their local CVS or Walgreens, he said, and physicians default to prescribing there.
He put the barrier in perception, not coverage: commercial plans cover "north of 80% of commercial lives," he said. Doctors worry about effort and cost, and he said finding BlinkRx in the electronic record takes about 10 seconds.
The $0 copay, rolled out at the end of the third quarter, is for commercially insured patients whose plan covers Voquezna. It is not available to government-insured patients, and Massachusetts is excluded because of state restrictions. The existing program already brought copays down to $25.
Cost of the free copay
Chief Financial and Business Officer Sanjeev Narula said the effect on gross-to-net, the gap between list and net price, is insignificant. Incremental scripts, he said, will more than offset the added cost.
A Craig-Hallum analyst asked what share of scripts goes through BlinkRx. Basta said the company would "pass on providing the specific numbers," though he said more new-to-brand scripts are landing there than before the push.
A slow build into 2027
Basta said the benefit is gradual because a new prescription becomes meaningful volume through refills over months. A script sent in November or December yields one fill in December but possibly three in the first quarter, so the push weighs more on 2027 than on the fourth quarter. Management expects better visibility over the next several quarters.
Phathom filled about 380,000 Voquezna prescriptions in the third quarter, about 248,000 of them covered, the company said. Revenue rose about 71% from a year earlier and 14% from the second quarter. The company reiterated full-year revenue guidance of $310 million to $325 million.
Basta said the company is not giving 2027 guidance yet and will do so on its call in January or February.
Sources
- Phathom Pharmaceuticals Non-GAAP EPS of $0.04 beats by $0.01, revenue of $84.7M misses by $0.12M (PHAT:NASDAQ) | Seeking Alpha — seekingalpha.com
- Phathom Pharmaceuticals Q3 2026 Earnings Preview | Seeking Alpha — seekingalpha.com
- Phathom Pharmaceuticals Provides Update on FDA Litigation — Yahoo Finance
- Phathom Pharmaceuticals Reports Third Quarter 2026 — rss.globenewswire.com